-
2024-511658-28-01
5
2021-04-06
primary sclerosing cholangitis
-
2023-506962-30-00
5
2021-03-29
Non-alcoholic steatohepatitis (NASH)
-
2023-507263-19-00
5
2020-12-23
Advanced Non-Small Cell Lung Cancer
-
2024-514104-14-00
4
2020-11-04
Adults subjects with advanced malignant pleural (cohort A) or peritone
-
2024-516673-68-00
5
2020-10-27
Human papillomavirus (HPV)-positive oropharyngeal cancer
-
2023-508635-31-00
5
2019-12-03
Hepatocellular Carcinoma
-
2024-510626-89-00
5
2019-11-18
Non-Alcoholic Steatohepatitis (NASH)
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2024-512667-31-00
5
2019-04-23
Main cohort: Patients with unresected Stage I/II, lymph-node negative
-
2024-510605-28-00
5
2018-11-27
Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer
-
2024-513027-16-00
4
2018-05-28
Resectable mucosal melanomas
-
2023-508726-10-00
5
2018-03-28
Hepatocellular Carcinoma
-
2024-518741-21-00
4
2014-12-23
colon cancer
-
2024-515996-37-00
3
2021-07-30
peritoneal carcinosis of ovarian origin cancer
-
2024-514228-18-00
4
2025-01-16
Asthma in adults who remain uncontrolled despite medium to high dose I
-
2024-517751-13-01
4
2024-12-26
Psychiatric disorders
-
2023-509684-24-00
7
2024-10-31
Hepatitis B
-
2024-511998-30-00
5
2024-10-18
Narcolepsy with Cataplexy (Narcolepsy Type 1)
-
2023-506000-50-00
4
2024-09-26
Adult Patients with Moderate-to-Severe Asthma Uncontrolled on Medium-H
-
2023-508465-32-00
5
2024-09-03
Narcolepsy with Cataplexy (Narcolepsy Type 1)
-
2023-509573-23-00
4
2024-07-16
Chronic HBV Infection
-
2023-508663-70-00
4
2024-06-18
Bronchiectasis
-
2022-502899-23-00
5
2024-04-23
Hepatic Encephalopathy (OHE)
-
2023-503693-20-01
5
2024-04-10
Severe eosinophilic asthma